EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitVergleichsstudieOpen Access · CC BY 4.0

Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies

Mayu Shiomi, Ryu Watanabe iD, Ryuhei Ishihara, Sayaka Tanaka, Takashi Nakazawa, Motomu Hashimoto

Biomolecules · 2025

DOI: 10.3390/biom15040544 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2025. Verfasst von Mayu Shiomi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Osaka Saiseikai Nakatsu Hospital, Osaka 530-0012, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Granulomatosis with Polyangiitis, Interleukin-5. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eosinophilic granulomatosis with polyangiitis (EGPA) is a necrotizing vasculitis characterized by extravascular granulomas and eosinophilia in both blood and tissues. Eosinophils, which play a critical role in the pathophysiology of EGPA, require interleukin (IL)-5 for maturation in the bone marrow and migration to tissues. Glucocorticoids and immunosuppressants have been the cornerstone of treatment; however, their side effects have imposed a significant burden on many patients. Mepolizumab, an antibody that binds to and neutralizes IL-5, demonstrated efficacy in controlling disease activity in EGPA in the MIRRA trial conducted in 2017. In 2024, benralizumab, an IL-5 receptor alpha antagonist, was shown to be non-inferior to mepolizumab in efficacy against EGPA in the MANDARA trial. Both drugs were originally used for severe asthma and have benefited EGPA by reducing eosinophil counts. Due to differences in pharmacological structure and pharmacokinetics, the degree of eosinophil suppression varies between the two agents, and recent studies suggest that they may also affect inflammatory and homeostatic eosinophils differently. This review summarizes the latest insights into the pathophysiology of EGPA, highlights the similarities and differences between the two drugs, and discusses future treatment strategies for EGPA based on current clinical unmet needs, including drug selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGranulomatosis with PolyangiitisInterleukin-5AnimalsHumansEosinophils

Stichwörter der Autor:innen

benralizumabeosinophileosinophilic granulomatosis with polyangiitisinterleukin-5mepolizumab

Substanzen

Antibodies, Monoclonal, HumanizedbenralizumabIL5 protein, humanInterleukin-5mepolizumab

Autor:innen und Institutionen

  • Department of Rheumatology, Osaka Saiseikai Nakatsu Hospital, Osaka 530-0012, Japan.
  • Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-Ku, Osaka 545-8585, Japan.
  • Department of Pathology, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.

ORCID-Profile: Ryu Watanabe

Zitieren

APA

Shiomi, M., Watanabe, R., Ishihara, R., Tanaka, S., Nakazawa, T., & Hashimoto, M. (2025). Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies. Biomolecules. https://doi.org/10.3390/biom15040544

Vancouver

Shiomi M, Watanabe R, Ishihara R, Tanaka S, Nakazawa T, Hashimoto M. Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies. Biomolecules. 2025. doi:10.3390/biom15040544

BibTeX
@article{Shiomi2025,
  author = {Shiomi, Mayu and Watanabe, Ryu and Ishihara, Ryuhei and Tanaka, Sayaka and Nakazawa, Takashi and Hashimoto, Motomu},
  title = {Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15040544}
}
Kostenlos starten →